Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627088 | 0.97 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL18027829 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL16627089 | 0.81 | MTNR1A (0.45) | SMN1; SMN2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL17955253 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL17955306 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL16624662 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL17955296 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL31658237 | 0.78 | SMN1; SMN2 (0.97) | SMN1; SMN2MEN1LMNAKMT2AKDM4E | |
| SCHEMBL16627109 | 0.77 | CYP1A2 (0.47) | SMN1; SMN2MEN1KMT2AKDM4EHPGD | |
| SCHEMBL23365654 | 0.76 | SMN1; SMN2 (0.79) | SMN1; SMN2MEN1LMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | SMN1; SMN2 2042/4885MEN1 3557/4885LMNA 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.